Literature DB >> 34460254

Biodistribution of Adeno-Associated Virus Serotype 5 Viral Vectors Following Intrathecal Injection.

Kelsey R Pflepsen1, Cristina D Peterson2, Kelley F Kitto2, Maureen S Riedl2, R Scott McIvor3, George L Wilcox2,4,5, Lucy Vulchanova2, Carolyn A Fairbanks1,2,4.   

Abstract

The pharmacokinetic profile of AAV particles following intrathecal delivery has not yet been clearly defined. The present study evaluated the distribution profile of adeno-associated virus serotype 5 (AAV5) viral vectors following lumbar intrathecal injection in mice. After a single bolus intrathecal injection, viral DNA concentrations in mouse whole blood, spinal cord, and peripheral tissues were determined using quantitative polymerase chain reaction (qPCR). The kinetics of AAV5 vector in whole blood and the concentration over time in spinal and peripheral tissues were analyzed. Distribution of the AAV5 vector to all levels of the spinal cord, dorsal root ganglia, and into systemic circulation occurred rapidly within 30 min following injection. Vector concentration in whole blood reached a maximum 6 h postinjection with a half-life of approximately 12 h. Area under the curve data revealed the highest concentration of vector distributed to dorsal root ganglia tissue. Immunohistochemical analysis revealed AAV5 particle colocalization with the pia mater at the spinal cord and macrophages in the dorsal root ganglia (DRG) 30 min after injection. These results demonstrate the widespread distribution of AAV5 particles through cerebrospinal fluid and preferential targeting of DRG tissue with possible clearance mechanisms via DRG macrophages.

Entities:  

Keywords:  AAV5 vector; gene therapy; lumbar intrathecal injection; mouse; pharmacokinetics; qPCR

Mesh:

Substances:

Year:  2021        PMID: 34460254      PMCID: PMC8519182          DOI: 10.1021/acs.molpharmaceut.1c00252

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   5.364


  58 in total

1.  Upregulated expression of Iba1 molecules in the central nervous system of mice in response to neurovirulent influenza A virus infection.

Authors:  I Mori; Y Imai; S Kohsaka; Y Kimura
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

Review 2.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

3.  The penetration of particulate matter from the cerebrospinal fluid into the spinal ganglia, peripheral nerves, and perivascular spaces of the central nervous system.

Authors:  J B BRIERLEY
Journal:  J Neurol Neurosurg Psychiatry       Date:  1950-08       Impact factor: 10.154

4.  Iba1-expressing microglia respond to herpes simplex virus infection in the mouse trigeminal ganglion.

Authors:  Isamu Mori; Fumi Goshima; Tetsuo Koshizuka; Yoshinori Imai; Shinichi Kohsaka; Naoki Koide; Tsuyoshi Sugiyama; Tomoaki Yoshida; Takashi Yokochi; Yoshinobu Kimura; Yukihiro Nishiyama
Journal:  Brain Res Mol Brain Res       Date:  2003-12-12

5.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

6.  Primary structure of the Aequorea victoria green-fluorescent protein.

Authors:  D C Prasher; V K Eckenrode; W W Ward; F G Prendergast; M J Cormier
Journal:  Gene       Date:  1992-02-15       Impact factor: 3.688

7.  Dorsal root ganglion - a potential new therapeutic target for neuropathic pain.

Authors:  Damir Sapunar; Sandra Kostic; Adriana Banozic; Livia Puljak
Journal:  J Pain Res       Date:  2012-02-16       Impact factor: 3.133

8.  Axonal transport of adeno-associated viral vectors is serotype-dependent.

Authors:  E A Salegio; L Samaranch; A P Kells; G Mittermeyer; W San Sebastian; S Zhou; J Beyer; J Forsayeth; K S Bankiewicz
Journal:  Gene Ther       Date:  2012-03-15       Impact factor: 5.250

9.  Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.

Authors:  S J Gray; S Nagabhushan Kalburgi; T J McCown; R Jude Samulski
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.